Skip to main content
Journal cover image

Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.

Publication ,  Journal Article
Galadanci, NA; Abdullahi, SU; Ali Abubakar, S; Wudil Jibir, B; Aminu, H; Tijjani, A; Abba, MS; Tabari, MA; Galadanci, A; Borodo, AM; Belonwu, R ...
Published in: American journal of hematology
September 2020

Altmetric Attention Stats
Dimensions Citation Stats

Published In

American journal of hematology

DOI

EISSN

1096-8652

ISSN

0361-8609

Publication Date

September 2020

Volume

95

Issue

9

Start / End Page

E247 / E250

Related Subject Headings

  • Stroke
  • Nigeria
  • Male
  • Immunology
  • Hydroxyurea
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Anemia, Sickle Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Galadanci, N. A., Abdullahi, S. U., Ali Abubakar, S., Wudil Jibir, B., Aminu, H., Tijjani, A., … DeBaun, M. R. (2020). Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. American Journal of Hematology, 95(9), E247–E250. https://doi.org/10.1002/ajh.25900
Galadanci, Najibah A., Shehu U. Abdullahi, Shehi Ali Abubakar, Binta Wudil Jibir, Hauwa Aminu, Aliyu Tijjani, Muhammad S. Abba, et al. “Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.American Journal of Hematology 95, no. 9 (September 2020): E247–50. https://doi.org/10.1002/ajh.25900.
Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, Aminu H, Tijjani A, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. American journal of hematology. 2020 Sep;95(9):E247–50.
Galadanci, Najibah A., et al. “Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.American Journal of Hematology, vol. 95, no. 9, Sept. 2020, pp. E247–50. Epmc, doi:10.1002/ajh.25900.
Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, Aminu H, Tijjani A, Abba MS, Tabari MA, Galadanci A, Borodo AM, Belonwu R, Salihu AS, Rodeghier M, Ghafuri DL, Covert C Greene BV, Neville K, Kassim AA, Kirkham FJ, Jordan LC, Aliyu MH, DeBaun MR. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. American journal of hematology. 2020 Sep;95(9):E247–E250.
Journal cover image

Published In

American journal of hematology

DOI

EISSN

1096-8652

ISSN

0361-8609

Publication Date

September 2020

Volume

95

Issue

9

Start / End Page

E247 / E250

Related Subject Headings

  • Stroke
  • Nigeria
  • Male
  • Immunology
  • Hydroxyurea
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Anemia, Sickle Cell